20 / 22
E u r o S c i C o n C o n f e r e n c e o n
PEDIATRICS
2017
Pediatrics 2017
Volume:3 Issue:4(Suppl)
Journal of Pediatric Care
ISSN 2471-805X
N o v e m b e r 1 3 - 1 4 , 2 0 1 7
L o n d o n , U K
Page 46
J Pediatr Care 2017, 3:4(Suppl)
DOI: 10.21767/2471-805X-C1-003
P
ANDAS as a distinct clinical entity has been a source of
controversies from its initiation in 1996-1998. In recent
years (2010 until now) it has been receiving wide attention
in scientific publications and it has been finally accepted as
a valid clinical diagnosis. The purpose of this presentation
is to review current diagnostic and therapeutic protocols
applicable to PANDAS and to report on long term outcomes
of patients receiving the recommended treatment(s).
Although most medical literature reports to date address
pediatric population affected by this syndrome specifically,
this report also addresses incidence, diagnostic and
therapeutic protocols for adolescents and young adults with
PANDAS. Consequently, it appears that in a specific cohort
of adolescent and young adult population diagnosed with
PANDAS treatments otherwise used in children may indeed
be an effective therapeutic alternative
kwangkim@jhmi.eduMiroslav Kovacevic
University of Illinois at Chicago College of
Medicine, USA
Long term outcomes
of patients diagnosed
with PANDAS
(Pediatric Autoimmune
Neuropsychiatric
Disorder associated with
group A Streptococcus
- a 17 years prospective
clinical study